4SCAR-CD44v6 t cell therapy for cancer patients
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment using your own immune cells, called T cells, which are modified in a lab to find and attack cancer cells that have a specific marker called CD44v6. It is for patients whose tumors show this marker and who are generally well enough to undergo cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 6 months old.
- Your tumor has been tested and shows the CD44v6 marker.
- You are able to do most daily activities on your own (KPS score > 70) and doctors expect you to live more than 3 months.
- Your heart, lungs, liver, kidneys, and blood counts are working well enough based on lab tests.
- You are not pregnant or breastfeeding, and you do not have active infections like HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (4SCAR7U) designed to target and kill cancer cells that carry a protein called CD7. It is for people with blood cancers that have not responded to other treatments.
This trial tests a new therapy where your immune cells are modified to better recognize and attack breast cancer cells. It is for people with advanced or recurrent breast cancer that has certain markers on the tumor cells.
This trial tests a new type of immune cell therapy (multi-CAR T cells) designed to target and kill cancer cells that have a marker called CD7. It may help people with certain blood cancers that have not responded well to other treatments.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
Hear when a new Cancers Which Are CD44v6 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.